You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

CRINONE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Crinone patents expire, and what generic alternatives are available?

Crinone is a drug marketed by Allergan and is included in one NDA.

The generic ingredient in CRINONE is progesterone. There are fifty-seven drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the progesterone profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Crinone

A generic version of CRINONE was approved as progesterone by FRESENIUS KABI USA on April 25th, 2001.

  Try a Trial

Drug patent expirations by year for CRINONE
Drug Prices for CRINONE

See drug prices for CRINONE

Recent Clinical Trials for CRINONE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
IBSA Institut Biochimique SAPhase 3
Merck Serono Co., Ltd., Beijing, ChinaPhase 4
Merck Serono Co., Ltd.Phase 4

See all CRINONE clinical trials

Pharmacology for CRINONE
Drug ClassProgesterone

US Patents and Regulatory Information for CRINONE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan CRINONE progesterone GEL;VAGINAL 020701-001 Jul 31, 1997 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Allergan CRINONE progesterone GEL;VAGINAL 020701-002 Jul 31, 1997 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for CRINONE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan CRINONE progesterone GEL;VAGINAL 020701-001 Jul 31, 1997 ⤷  Try a Trial ⤷  Try a Trial
Allergan CRINONE progesterone GEL;VAGINAL 020701-001 Jul 31, 1997 ⤷  Try a Trial ⤷  Try a Trial
Allergan CRINONE progesterone GEL;VAGINAL 020701-002 Jul 31, 1997 ⤷  Try a Trial ⤷  Try a Trial
Allergan CRINONE progesterone GEL;VAGINAL 020701-002 Jul 31, 1997 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for CRINONE

See the table below for patents covering CRINONE around the world.

Country Patent Number Title Estimated Expiration
Germany 69415543 ⤷  Try a Trial
Philippines 30813 Novel method of progesterone and effect thereof. ⤷  Try a Trial
Denmark 0719146 ⤷  Try a Trial
Australia 689133 ⤷  Try a Trial
Canada 2171939 NOUVELLE METHODE D'ADMINISTRATION DE LA PROGESTERONE, REDUISANT LE RISQUE D'EFFETS SECONDAIRES (NOVEL METHOD OF PROGESTERONE DELIVERY AND AFFECT THEREOF) ⤷  Try a Trial
Norway 961044 ⤷  Try a Trial
Germany 3485995 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for CRINONE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2782584 21C1058 France ⤷  Try a Trial PRODUCT NAME: COMPOSITION CONTENANT A LA FOIS DE L'ESTRADIOL (17SS-ESTRADIOL), Y COMPRIS SOUS FORME HEMIHYDRATEE, ET DE LA PROGESTERONE; NAT. REGISTRATION NO/DATE: NL51886 20210421; FIRST REGISTRATION: BE - BE582231 20210406
2782584 2021C/558 Belgium ⤷  Try a Trial PRODUCT NAME: COMPOSITION CONTENANT A LA FOIS DE L'ESTRADIOL (17--ESTRADIOL), EVENTUELLEMENT SOUS FORME D'UN SEL, HYDRATE OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI (Y COMPRIS SOUS FORME HEMIHYDRATEE), ET DE LA PROGESTERONE; AUTHORISATION NUMBER AND DATE: BE582231 20210406
2782584 301153 Netherlands ⤷  Try a Trial PRODUCT NAME: COMPOSITION CONTAINING BOTH ESTRADIOL (17SS-ESTRADIOL), OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE OR SOLVATE THEREOF (INCLUDING IN HEMIHYDRATE FORM), AND PROGESTERONE; NATIONAL REGISTRATION NO/DATE: RVG 125821 20210611; FIRST REGISTRATION: BE BE582231 20210406
2782584 132021000000197 Italy ⤷  Try a Trial PRODUCT NAME: ESTRADIOLO (17SS-ESTRADIOLO) IN PARTICOLARE NELLA FORMA EMIIDRATA, E PROGESTERONE COMPRENDENTI LE VARIE FORME DI ESTRADIOLO (17SS-ESTRADIOLO), QUALI LE FORME IDRATE E SOLVATATE, INCLUDENDO LA FORMA EMIIDRATA, ED I SUOI SALI.(BIJUVA); AUTHORISATION NUMBER(S) AND DATE(S): BE582231, 20210406;048335018 -048335020, 20210517
2782584 LUC00245 Luxembourg ⤷  Try a Trial PRODUCT NAME: COMPOSITION CONTENANT A LA FOIS DE L'ESTRADIOL (17SS-ESTRADIOL), EVENTUELLEMENT SOUS FORME D'UN SEL, HYDRATE OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI (Y COMPRIS SOUS FORME HEMIHYDRATEE), ET DE LA PROGESTERONE; AUTHORISATION NUMBER AND DATE: BE582231 20210701
0113964 97C0037 Belgium ⤷  Try a Trial PRODUCT NAME: OESTROGENES EQUINS CONJUGUES; ACETATE DE MEDROXYPROGESTERONE; NAT. REGISTRATION NO/DATE: NL 19569 19950301; FIRST REGISTRATION: CH - 52647 01 010 19940826
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.